库欣综合征演变过程中的脂肪性肝病
该单中心回顾性研究纳入49例库欣综合征患者,诊断时肝/脾密度比<1定义为肝脂肪变,13例(26.5%)存在肝脂肪变且均为代谢功能障碍相关脂肪性肝病(MASLD)。多变量分析显示2型糖尿病患病率更高和甘油三酯水平更高与肝脂肪变相关,库欣综合征的强度或持续时间无差异。
要点
- 库欣综合征诊断时肝脂肪变患病率为26.5%(13/49),均为MASLD。
- 肝脂肪变患者的多变量分析显示2型糖尿病患病率更高、甘油三酯水平更高。
- 库欣综合征缓解后随访影像的4例中3例肝脂肪变缓解,无MASLD者肝/脾比未恶化。
核心结论
- 库欣综合征诊断时肝脂肪变患病率估计为26.5%,代谢因素的存在与肝脂肪变的发生相关。
研究设计与样本
- 法国昂热医院2010年至2020年的单中心回顾性研究,纳入49例诊断时具备腹部影像的库欣综合征患者。
- 以计算机断层扫描平均肝/脾密度比<1诊断肝脂肪变,并对肝脂肪变患者计算FIB-4、NAFLD Fibrosis Score和eLIFT等预测肝纤维化的简易临床-生物学评分。
主要发现
- 49例中13例(26.5%)在库欣综合征诊断时存在肝脂肪变,13例均为MASLD。
- 多变量分析中,这些患者2型糖尿病患病率更高且甘油三酯水平更高。
- 库欣综合征的强度或持续时间无差异。
- 13例MASLD中2例(15.4%)有显著纤维化预测评分。
- 库欣综合征缓解后行随访影像的4例中,3例在缓解后1至5年间肝脂肪变缓解;诊断时无MASLD的患者缓解后肝/脾比无恶化。
关键数值与推荐
- 肝脂肪变诊断标准为计算机断层扫描平均肝/脾密度比<1。
- 肝脂肪变患病率为26.5%(13/49)。
- MASLD患者中显著纤维化预测评分比例为15.4%(2/13)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: The clinical manifestations of Cushing syndrome are variable, but an important number of patients present a metabolic syndrome, strongly associated with hepatic steatosis. OBJECTIVE: The aim of this study was to determine the prevalence of metabolic dysfunction associated steatotic liver disease (MASLD) at the diagnosis of Cushing syndrome. METHODS: We conducted a single-center retrospective study at Angers Hospital (France) between 2010 and 2020. Forty-nine patients followed for Cushing syndrome with available abdominal imaging at diagnosis were included. A mean liver/spleen density ratio < 1 on computed tomography was diagnostic of hepatic steatosis. Simple clinico-biological scores predictive of hepatic fibrosis (FIB-4, NAFLD Fibrosis Score, and eLIFT) were calculated for patients with hepatic steatosis. RESULTS: Of the 49 patients, 13 (26.5%) had hepatic steatosis at diagnosis of Cushing syndrome. All 13 had MASLD. These patients had a higher prevalence of type 2 diabetes and higher triglyceride levels in multivariate analysis. There was no difference according to the intensity or duration of Cushing syndrome. Among the 13 patients with MASLD, 2 (15.4%) had a significant fibrosis predictive score. Of the 4 patients with follow-up imaging after remission of Cushing syndrome, 3 had remission of steatosis between 1 and 5 years after remission of Cushing syndrome. No patient without MASLD at diagnosis had a worsening liver/spleen ratio after remission. CONCLUSION: We estimated the prevalence of hepatic steatosis at the diagnosis of Cushing syndrome at 26.5%. The presence of metabolic factors was associated with the occurrence of hepatic steatosis.
引用
- Marengo M, Briet C, Munier M, et al. Fatty Liver Disease Along Cushing Syndrome Evolution. J Clin Endocrinol Metab. 2025. PMID: 39193719. doi:10.1210/clinem/dgae568
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。